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Introductory Paragraph 
Temple-Baraitser syndrome (TBS) is a multi-system developmental disorder characterized by 
intellectual disability, epilepsy and hypoplasia or aplasia of the nails of the thumb and great 
toe1,2. Here we report damaging de novo mutations in KCNH1 (Ether-A-Go-Go, EAG1, KV10.1), 
a voltage-gated potassium channel that is predominantly expressed in the central nervous 
system (CNS), in six TBS individuals. Characterization of these mutations in both Xenopus 
oocytes and human HEK293T cells revealed decreased threshold of activation and delayed 
deactivation, demonstrating that TBS-associated KCNH1 mutations lead to deleterious gain-of-
function. Consistent with this result, we find that two TBS mothers with epilepsy, but who are 
otherwise healthy, are low-level (10% and 27%) mosaic carriers of pathogenic KCNH1 
mutations. Consistent with recent reports3-8, this demonstrates that the etiology of many 
unresolved central nervous systems disorders, including epilepsies, may be explained by 
pathogenic mosaic mutations. 
 
Main text 
TBS [MIM: 611816], which was first formally described in 1991, has a wide and severe 
phenotypic spectrum that includes intellectual disability, seizures, and dysmorphic features1,2 
(Fig. 1). TBS is rare, with only five cases reported to date, although it is possible that TBS is 
largely unrecognized by the clinical community and therefore under-reported9. The disease is 
sporadic in nature, and although a genetic etiology has been suspected10, the lack of familial 
recurrence or defined cohorts has inhibited attempts to identify the genetic basis of the disease. 
In this study we recruited six unrelated TBS individuals and their parents for analysis by whole 
exome sequencing (Table 1 and Supplementary Note). This study was approved by the Royal 
Brisbane and Women’s Hospital Human Research Ethics Committee, The Royal Children’s 
Hospital Human Research Ethics Committee, and The University of Queensland Medical 
Research Ethics Committee. Informed consent was obtained from all study subjects. DNA was 
isolated from peripheral blood from all participants, and in select cases also from saliva and 
buccal cells. Exome sequencing and analysis was performed on all six probands and four sets 
of parents (Online Methods). A minimum of 19 Gb of sequence was generated for each 
individual, yielding a mean depth of 165-fold coverage and an average of 93% of target bases 
sequenced at 20X. 
Given the severity of the TBS phenotype and its sporadic presentation, we first queried for 
pathogenic de novo mutations in the four cases for which exomes of the full family trio were 
sequenced (cases A-D). Using pedigree informed variant calling we filtered for candidates that 
were only detected in the proband, computationally predicted to be damaging11,12 and were 
absent from dbSNP 141, the 1000 Genomes Project and the NHLBI ESP6500 databases. This 
revealed that the TBS individuals carried missense de novo mutations in the voltage-gated 
potassium channel gene, KCNH1 (MIM 603305; NM_172362; Table 1; Fig. 2a). Subsequent 
investigation of the two proband-only exomes (cases E and F) also revealed damaging KCNH1 
missense variants, which were similarly absent from all public variant databases and shown to 
  3 
be de novo by targeted Sanger sequencing of both parents (Table 1). All TBS-associated 
KCNH1 mutations were absent from an in-house control exome dataset from more than 100 
family trios of children with neurological disorders.  
Evaluation of the TBS family case histories revealed that the mothers of two subjects (A.1 and 
B.1) had been previously diagnosed with epilepsy but presented with no other phenotypic 
features suggestive of TBS (Table 1 and Supplementary Note). In light of recent reports of 
pathogenic mosaicism in a range of neurological disorders3-8, this suggested the potential for 
low-level KCNH1 mutation mosaicism in these individuals. Directed reanalysis of exome 
sequence reads revealed that although both A.1 and B.1 had KCNH1 genotype calls of 
“homozygous wild type” at the sites of mutation, a small proportion of reads supported the 
disease allele associated with their children and was not observed in the subjects’ fathers 
(Table 1).  
To confirm maternal mosaicism we performed targeted high-depth sequencing of KCNH1 exon 
eight and obtained more than 40,000-fold coverage for each sample (Supplementary Table 2). 
In subject A.1 the NM_172362.2:c.1508A>G variant was confirmed at very low, but detectable, 
levels: 4.7% of reads from two independently drawn blood samples, and 3.4% and 4.5% of 
reads from fibroblast and saliva samples, respectively (Supplementary Table 2). In B.1 the 
NM_172362.2:c.1465C>T mutation was detected in 13.6% of reads from targeted reanalysis of 
DNA from peripheral blood (Supplementary Table 2).  
KCNH1 is a highly conserved member of the EAG subfamily of voltage-gated potassium 
channels. It is predominantly expressed in the adult CNS, but restricted cell populations 
expressing KCNH1 have been identified throughout the human body13. KCNH1 is expressed in 
~70% of solid tumors14 and inhibition of KCNH1 activity has been shown to restrict cancer cell 
proliferation15. Relatively little is known about the normal physiological function of KCNH1. It 
has, however, been identified as a regulator of cell proliferation in bone marrow derived 
mesenchymal stem cells16, and its activity appears to be cell-cycle regulated17, suggesting that it 
is likely to be involved in fundamental cellular and developmental processes. Indeed, KCNH1 is 
predicted to be in the 7th percentile of genes intolerant to functional genetic variation18. 
KCNH1 channels are homotetramers, with each subunit composed of six transmembrane 
helices flanked by cytoplasmic C-terminal and N-terminal domains (Fig. 2b). Remarkably, three 
of the TBS subjects carry the same de novo heterozygous missense mutation 
(NM_172362.2:c.1480A>G, p.Ile494Val), and two other subjects have de novo mutations within 
30 bp of this mutation (NM_172362.2:c.1508A>G, p.Gln503Arg; NM_172362.2:c.1465C>T, 
p.Leu489Phe). These mutations all occur within exon eight and affect residues located in the S6 
transmembrane helix, which is a central component of the channel pore19 (Fig. 2b). The de 
novo mutation identified in the final subject lies in exon six (NM_172362.2:c.651G>C, 
p.Lys217Asn) and is located near the boundary between the N-terminal cytoplasmic domain 
and the S1 transmembrane helix (Fig. 2b). All four affected residues are highly conserved 
across the KCNH gene family (Fig. 2c). 
To determine the effect of these mutations on the biophysical properties of KCNH1, all four 
mutant channels were expressed in Xenopus laevis oocytes and Human Embryonic Kidney 
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293T (HEK293T) cells and investigated using two-electrode voltage clamp or patch-clamp 
electrophysiology, respectively. Activation of wild-type or mutant KCNH1 expressed in oocytes 
or HEK293T cells resulted in robust voltage-dependent outward currents, consistent with the 
expression of functional membrane-bound potassium channels (Fig. 3a,b and Supplementary 
Fig. 1a,b). In both systems, however, each of the four mutations showed a pronounced 
decrease in threshold of activation when compared to wild-type KCNH1 (Fig. 3c and 
Supplementary Fig. 1c). For example, in HEK293T cells, the voltage of half maximal activation 
(V1/2) of wild-type KCNH1 channels was 20.2 mV. In contrast, the V1/2 for all four mutant 
channels was negatively shifted by at least 33 mV compared to the wild-type channel, with 
values between –13.7 mV and –28.9 mV (Table 2). Deactivation was also profoundly affected, 
with all mutant channels closing more slowly than the wild-type (Fig. 3d and Supplementary 
Fig. 1d). These data indicate that all four de novo KCNH1 mutations identified in this study lead 
to gain-of-function.  
Taken together, these results demonstrate that mutations in KCNH1 can lead to deleterious 
channel activity and cause TBS. Furthermore, the phenotypic separation between two of the 
TBS patients and their mothers, who only suffer from epilepsy, may be the result of reduced 
mutational burden in the mosaic mothers. These findings are in contrast to studies of KCNH1 
knockout mice, which are viable and show phenotypic abnormalities limited to mild hyperactivity 
and sensitivity to haloperidol-induced catalepsy20. This suggests that KCNH1 loss-of-function 
mutations may be relatively well tolerated, but those resulting in aberrant channel activity are 
likely to be pathogenic. 
A wide range of genetic disorders have been associated with potassium channel mutations 
including at least thirteen forms of epilepsy21-23, several ataxias24,25 and a form of inherited 
deafness26. Developmental phenotypes associated with potassium channelopathies are less 
common, but not unprecedented. For example, Andersen-Tawil syndrome (MIM 170390), an 
autosomal dominant disorder resulting from mutations in KCNJ2, presents with distinctive 
dysmorphic features including scoliosis, low-set ears, wide-set eyes, small chin, and broad 
forehead27. We propose that both the CNS and developmental defects observed in TBS 
subjects result from hyperactive KCNH1, which disrupts both cell proliferation (or migration) and 
neuronal activity. 
Although many epilepsies are believed to have a genetic basis, a definitive diagnosis can only 
be provided in a minority of cases28. There is, however, a growing body of evidence indicating 
that genetic mosaicism is an important factor in the etiology of many neurological disorders29. 
For example, there have been several reports of epilepsy resulting from mosaic mutations in the 
ion channels SCN1A3-5 and KCNQ26,7, and a recent systematic investigation has found that 
mosaic mutations are frequent in patients with brain malformations8. Our results indicate that 
low level mosaicism in KCNH1 may also contribute to epilepsy, and together with the previously 
reported cases, highlights the need to develop novel informatic approaches to identify 
pathogenic mosaic variants in large-scale and diagnostic sequencing efforts. 
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Figures 
 
 
Figure 1. Phenotypic features of Temple-Baraitser Syndrome. (a) Facial features aged 2½ 
years and (b) 4 years. Note the myopathic facies, flat forehead, broad depressed nasal bridge, 
bilateral epicanthic folds, short columella, long shallow philtrum, and broad mouth with 
downturned corners. (c) Left hand (d) and left foot. Note broad adducted terminal thumb and 
nail hypoplasia of the thumb and nail aplasia of the great toe. (e) Radiographs of the left foot 
and (f) left hand. Note the radiolucencies in the distal phalanges. Consent to publish images of 
the subject was obtained. Images b-f reproduced with permission2. 
 
 
Figure 2. KCNH1 mutations in subjects with Temple-Baraitser Syndrome. (a) Genomic 
structure of the KCNH1 gene. The position of the TBS-associated de novo mutations are 
indicated in red. The transcription start site is shown as a blue arrow. (b) Schematic of the 
KCNH1 protein showing the six transmembrane helices (S1–S6), the intracellular N-terminal 
region containing an eag domain (EAG), and the C-terminal region containing a cyclic 
nucleotide binding homology domain (CNBHD). The locations of the TBS-associated de novo 
mutation sites are indicated by red stars. (c) Multiple sequence alignment of all eight human 
KCNH family proteins. The mutated KCNH1 residues are highlighted in bold. Conservation of 
residues across the gene family is indicated in red.  
 
 
Figure 3. Mutant KCNH1 channels show increased voltage sensitivity and delayed 
deactivation. (a) Representative families of whole-cell currents elicited by steps from –120 mV 
to +120 mV in 10 mV increments in HEK293T cells expressing wild-type (WT) and mutant 
KCNH1 (holding potential of –120 mV). The arrowheads represent zero current. (b) Plot of 
mean current density versus test voltage for WT and TBS mutant KCNH1 channels expressed 
in HEK293T cells. (c) Activation current-voltage relationship (±s.e.m.) for WT, p.Lys217Asn, 
p.Leu489Phe, p.Ile494Val and p.Gln503Arg expressed in HEK293T cells. Currents were 
measured at the end of the activation test pulse. (d) Fast and slow time constants (t) of 
deactivation for WT and mutant KCNH1 channels expressed in HEK293T cells, analyzed from 
the tail current at –140 mV following a maximally activating pre-pulse to +80 mV. Data are 
presented as mean ± s.e.m. with numbers of experiments indicated in parentheses. P-values 
calculated compared to WT using unpaired t-test with Welch’s correction. * P < 0.05, ** 
P < 0.01. 
 
 
 
 
  6 
Table 1: KCNH1 genotypes from exome sequencing. 
 
Family Individual Relationship Condition Genotype1 Wild-type 
reads  
Alternative 
reads  
A  A.0 Proband TBS c.1508A>G   90 71 
 A.1 Mother Epilepsy - 144   6 
 A.2 Father - - 142   0 
B  B.0 Proband TBS c.1465C>T   75 81 
 B.1 Mother Epilepsy - 102   8 
 B.2 Father - - 177   0 
C  C.0 Proband TBS c.1480A>G   73 96 
 C.1 Mother - - 135   0 
 C.2 Father - - 148   0 
D  D.0 Proband TBS c.651G>C   37 37 
 D.1 Mother - -   85   0 
 D.2 Father - - 115   0 
E  E.0 Proband TBS c.1480A>G   34 41 
F  F.0 Proband TBS c.1480A>G   36 26 
 
1 Genotype of KCNH1 (NM_172362) as called by rtgFamily variant caller. 
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Table 2: Voltage of half maximal activation values and slopes of the 
current-voltage relationships for WT and mutant KCNH1 channels. 
 
 
 X. laevis oocytes  HEK293T cells 
 V1/2 P Slope P  V1/2 P Slope P 
Wild-type  22.0±1.3 n.a. 19.7±1.1 n.a.   20.2±2.4 n.a. 17.0±0.9 n.a. 
p.Lys217Asn -18.0±1.7 
5.2x10-10 18.7±1.6 
0.433  -20.0±2.3 1.3x10-11 21.3±1.0 0.004 
p.Leu489Phe -23.5±1.4 7.4x10-15 16.1±1.2 0.011  -16.2±3.8 9.2x10-7 19.7±1.0 0.011 
p.Ile494Val -14.5±1.7 8.7x10-9 17.6±1.5 0.371  -13.7±2.5 2.7x10-9 21.1±1.1 0.064 
p.Gln503Arg -38.2±1.1 6.3x10-19 17.9±1.0 0.852  -28.9±2.3 8.1x10-14 19.3±0.7 0.052 
 
V1/2 and slope ± s.e.m. P-values calculated compared to WT using unpaired t-test with Welch’s correction. 
Significant P values are shown in bold. 
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Online Methods 
 
Exome and Amplicon sequencing 
DNA library preparation and exome enrichment was performed using the Illumina Nextera Rapid 
Capture kit. Captured libraries were sequenced on an Illumina HiSeq 2000 according to the 2 x 
100 bp paired-end read-sequencing protocol at the Queensland Centre for Medical Genomics. 
Reads were aligned to the reference human genome (GRCh37) and pedigree informed variant 
calling was performed using the Real Time Genomics (RTG) integrated analysis tool rtgFamily 
v3.230. All variants were annotated using SnpEff v3.431. Subsequent analysis and identification 
of candidate variants was performed with an in-house workflow incorporating the annotated 
variant data and pedigree information. 
 
Exons 6 and 8 of KCNH1 were PCR amplified with 60ºC annealing and a 1 min per kb 
extension time under Phusion Taq amplification conditions (see Supplementary Table 3 for 
primer sequences). MiSeq libraries were prepared from 1 ng of PCR product using the Nextera 
XT library preparation kits and sequenced using the MiSeq 300 cycle v2 kits as previously 
described32. The first 50,000 reads from each sample were quality trimmed using 
trimmomatic33, aligned to the reference human genome (GRCh37) using BWA-MEM34 and 
variants were called with Varscan235. 
 
DNA constructs 
Plasmids (pUC57) containing the wild-type coding sequence of KCNH1 isoform NM_002238 
along with p.Gln476Arg and p.Ile467Val versions (equivalent to p.Gln503Arg and p.Ile494Val in 
KCNH1 isoform NM_172362) were purchased from GenScript. Coding sequences were sub-
cloned into the pEF6 mammalian expression vector with the addition of a C-terminal HA epitope 
tag. Site directed mutagenesis was used to introduce p.Lys217Asn and p.Leu462Phe variants 
(equivalent to p.Lys217Asn and p.Leu489Phe in KCNH1 isoform NM_172362) into the  wild-
type construct.  
 
Oocyte Electrophysiology 
Channel function was assessed using two-electrode voltage-clamp experiments performed on 
Xenopus laevis oocytes expressing homomeric KCNH1 channels prepared as previously 
described36. wild-type and mutant KCNH1 cRNA was synthesized using an mMessage 
mMachine in vitro transcription kit (Ambion Inc., Austin, TX, USA) and injected at 4 ng per 
oocyte. Oocytes were incubated at 17°C in ND96 solution containing 96 mM NaCl, 2 mM KCl, 
1.8 mM CaCl2, 2 mM MgCl2, 5 mM HEPES, 5 mM pyruvate, 50 µg/ml gentamicin (pH 7.4), and 
horse serum (2.5%). Experiments were performed at room temperature (21–22°C) in ND96 
solution (as defined above, but minus serum, pyruvate and antibiotics) 1–2 days after cRNA 
injection. Oocytes were clamped at –100 mV (Axoclamp 900A) using electrodes of resistance 
0.5–0.8 MΩ when filled with 3 M KCl solution. The bath was constantly perfused and 3 M KCl 
agar bridges were used to ground the bath. To test the voltage-dependent activation of KCNH1 
channels, 2 s pulses from –120 mV to +80 mV in 20 mV steps were used to activate the 
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channel from holding potential of –100 mV, followed by a 1 s step to –110 mV with a 15 second 
pulse interval. The currents elicited by the test pulse were normalized to Imax, plotted against test 
voltage and fitted with Boltzmann equation. The deactivation of KCNH1 channels was studied 
by first activating the channel at +80 mV for 1000 ms, then deactivating the channel with steps 
from –120 mV to 0 mV for 1500 ms before returning to holding potential of –100 mV with a 30 
second pulse interval. The kinetics of deactivation was analyzed by fitting the deactivation at –
90 mV with a double exponential equation (Clampfit10) and the Tau values compared using an 
unpaired t-test with Welch’s correction. Voltage-dependence of steady-state inactivation was 
studied using the double-pulse protocol reported previously37. A 10 s conditioning pulse 
increasing from –130 mV to +35 mV in 15 mV steps (Vpre) preceded an activating 4.5 s test 
pulse to +30 mV every 30 s (Suppl Fig. 1b). The current elicited by the test pulse was 
normalized to Imax and plotted against conditioning voltage. Data acquisition and analysis were 
performed using pCLAMP10 software (Molecular Devices). Significant difference is defined as P 
<0.05 (unpaired t-test with Welch’s correction). n-values represent experiments from individual 
oocytes taken from at least three different frogs. 
 
HEK293T Patch clamp Electrophysiology 
HEK293T cells (CRL-11268, American Type Culture Collection) were cultured in DMEM 
supplemented with 10% FBS and 1% penicillin-streptomycin. Cells were tested negative for 
mycoplasma. To carry out electrophysiology studies in mammalian cells, HEK293T cells were 
transiently transfected with 2 μg of plasmid DNA (1 μg for p.Leu462Phe mutant) using 
Lipofectamine 2000 (Life Technologies) according to the manufacturers instructions. Patch-
clamp experiments were conducted 24h post transfection at room temperature in the whole-cell 
configuration using an Axon MultiClamp 700B patch-clamp amplifier and associated standard 
equipment (Molecular Devices). Cells were continuously superfused with bath solution 
containing 140 mM NaCl, 2.5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 8 mM glucose and 10 mM 
HEPES, adjusted to pH 7.4 with NaOH. Patch pipettes were pulled from borosilicate glass and 
typically had a resistance of 2-5 MΩ when filled with the standard pipette solution containing 
70 mM KF, 60 mM KCl, 15 mM NaCl, 5 mM EGTA-Na, 5 mM HEPES, adjusted to pH 7.2 with 
NaOH. Series resistance did not exceed 5 MΩ and was 70-80% compensated. Acquired 
currents were filtered at 1 kHz, sampled at 10 kHz, collected and analyzed using Clampex 10.0 
Software (Molecular Devices).  
 
To test the voltage-dependent activation of KCNH1 channels, 1 s pulses from –120 mV to +120 
mV in 10 mV steps were used to activate the channel from holding potential of –120 mV, 
followed by a 400 ms step to –100 mV. The currents elicited by the test pulse were normalized 
to Imax, plotted against the test voltage and fitted with Boltzmann equation. The deactivation of 
KCNH1 channels was studied by first activating the channel at +80 mV for 800 ms, then 
deactivating the channel with steps from –140 mV to 0 mV for 500 ms before returning to 
holding potential of –120 mV. The kinetics of deactivation were analyzed by fitting the 
deactivation sweep at –140 mV with double exponential equation (Clampfit10) and the Tau 
values compared using an unpaired t-test with Welch’s correction.  
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